0.6320USD+3.44%Mkt Cap: 4.79M USDP/E: —Last update: 2026-05-22
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a …
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap4.79M USD
Enterprise Value-11.63M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-1.92M USD
Revenue/Share—
Last Price0.6320 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees4
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.75
PEG—
EV/EBITDA3.60
EV/Revenue—
P/S—
P/B0.54
EPS (TTM)-0.48
EPS (Forward)-0.35
52W Range
0.53102% of range7.000
52W High7.000 USD
52W Low0.5310 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-20.16%
ROA-10.92%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.26M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-101.68%
Net Debt-16.26M USD
Net Debt/EBITDA5.04
Balance Sheet
Debt/Equity0.00
Current Ratio2.12
Quick Ratio2.10
Book Value/Sh1.135 USD
Cash/Share2.146 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:50
Split DateJan 16, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.6.73M
Float5.35M
Insiders4.30%
Institutions9.47%
Short Interest
Short Ratio1.9d
Short % Float1.07%
Short % Out.0.95%
Shares Short72.11K
Short (prev mo.)125.43K
Technical
SMA 500.7480 (-15.5%)
SMA 2001.149 (-45.0%)
Beta2.11
S&P 52W Chg28.31%
Avg Vol (30d)43.24K
Avg Vol (10d)50.94K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—